Bosakitug

N/A

Report date: 2025/02/10 15:37:10
First In Class

Base Information

Drug NameBosakitug
Drug Alias NameBSI-045BTQC-2731TQC2731ATI-045
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)EczemaDermatitis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBiosion Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiosion IncShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdAclaris Therapeutics Inc +[5] 
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)EczemaDermatitis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A